XBiotech Inc Dossier - Source-backed chat

XBiotech Inc

XBITNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.89

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.19Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $66.8M

Enterprise Value −$42.8M

Shares Outstanding 30.5M diluted

Next Earnings Date13 Nov 2026

Last ex-dividend15 Jul 2021

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

XBiotech is a clinical-stage biopharmaceutical company focused on discovering and developing True Human™ therapeutic antibodies derived from natural human immunity. Following the sale of its lead asset bermekimab to Janssen in 2019, the company transitioned to a pre-revenue platform model. While the company has historically operated with zero revenue and high cash burn, Q1 2026 results demonstrate a positive trend with narrowed net losses ($5.5 million vs. $10.9 million in Q1 2025) and a solid cash buffer of $115.5 million. Crucially, the company recently received FDA clearance to initiate its Phase II V-SPINE (PT064) study of vilamakitug in active axial spondyloarthritis, marking the resumption of its clinical rheumatology program. Given the speculative nature of its platform validation and the early stage of its resumed clinical pipeline, a Hold recommendation is warranted until clinical enrollment progress or platform partnerships materialize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.08

The bear case is triggered by clinical delays, safety holds, or poor efficacy signals in the V-SPINE trial, combined with an inability to secure platform partnerships. This would lead to continued cash depletion, forcing a dilutive capital raise or a strategic pause in development programs.

Base CaseCentral scenario

$2.34

The base case assumes steady progress in the Phase II V-SPINE trial with patient enrollment proceeding throughout 2026. Operating expenses remain controlled around $25-30 million annually, maintaining a cash runway of over 18 months. The stock trades in a consolidated range reflecting its clinical-stage, pre-revenue status.

Bull CaseUpside scenario

$15.28

The bull case is driven by rapid enrollment and positive interim data from the Phase II V-SPINE trial of vilamakitug, alongside the successful execution of a high-value platform licensing deal with a major pharmaceutical partner. This would validate the True Human™ platform, provide non-dilutive upfront cash, and establish a clear path to commercialization.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong balance sheet with $115.5 million in cash and cash equivalents as of March 31, 2026, providing a runway for near-term development.
Resumption of the clinical rheumatology program with FDA clearance of the Phase II V-SPINE study for vilamakitug.
Proprietary True Human™ antibody platform that leverages natural human immunity, offering potential safety and efficacy advantages over engineered antibodies.

Key Investment Risks

Pre-revenue status with zero expected revenue in 2026 and ongoing operating losses.
High dependence on a single clinical-stage candidate (vilamakitug) and platform validation through unpredictable licensing deals.
Historical volatility and negative market reactions to clinical updates, combined with a lack of near-term commercial products.

Thesis Invalidation Triggers

FDA clinical hold on the Phase II V-SPINE trial of vilamakitug.
Quarterly cash burn accelerating significantly beyond expectations, reducing the runway to less than 12 months.
Failure to enroll the first patient in the V-SPINE study by the end of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.